Morningstar

LEO Pharma continues global rollout of Anzupgo® (delgocitinib) cream with submission of New Drug Application in China

LEO Pharma A/S, a global leader in medical dermatology, has today announced submission of the New Drug Application (NDA) to the National Medical Products Administration (NMPA) in China for Anzupgo® ...
Morningstar

LEO Pharma Presents Late-Breaking Phase 3 Delgocitinib Cream Data in Adolescents with Moderate to Severe Chronic Hand Eczema (CHE)

LEO Pharma A/S, a global leader in medical dermatology, today presented two late-breaking delgocitinib cream presentations for Chronic Hand Eczema (CHE), showcasing the findings for the DELTA TEEN ...